What Is the Best Injection for Erectile Dysfunction?

Alprostadil, a synthetic form of prostaglandin E1, is the only FDA-approved drug for penile injection therapy and remains the most extensively studied single agent for erectile dysfunction. But “best” depends on what you mean. For many men, especially those who don’t respond well to alprostadil alone, a compounded combination called trimix (alprostadil plus papaverine plus phentolamine) has become the go-to in clinical practice. The choice between these options involves trade-offs in effectiveness, pain, side effects, cost, and how the drugs are stored, and the reality is messier than any single recommendation can capture.

Alprostadil on Its Own

Alprostadil works by relaxing the smooth muscle inside the penis, allowing blood to flow in and produce an erection. It’s been studied more rigorously than any other injectable for ED, and the numbers are strong. In a six-month self-injection study of 683 men, participants reported being able to have sex after about 94% of injections, with both the men and their partners rating the activity as satisfactory roughly 87% of the time.¹ Those are hard numbers to argue with.

A four-year European trial of over 16,000 recorded injections found that 93% resulted in erections rigid enough for intercourse. By the end of the study, over 90% of the men who completed the full course rated the treatment’s tolerability as good or very good, and their female partners reported similarly high satisfaction.² There’s also an interesting bonus: long-term use of alprostadil appears to help some men regain spontaneous erections. In one study, reports of spontaneous erections climbed from about 37% at baseline to 85% over the course of treatment, with ultrasound confirming improvements in penile blood flow.³

The main drawback of alprostadil is pain. About half of men experience penile pain at some point during treatment, though it occurs with only about 11% of individual injections and is usually described as mild.¹ A study looking specifically at a newer formulation found even lower pain rates, around 2-4% of injections.⁴ In men recovering from prostate surgery, pain scores averaged about 3 out of 10 at six months and dropped further by twelve months.⁵ Pain matters because it’s one of the factors that drives men away from injection therapy over time.

Trimix and Why Many Doctors Prefer It

Trimix blends three drugs: alprostadil, papaverine, and phentolamine. Each works through a different pathway to relax smooth muscle and increase blood flow, so combining them at lower individual doses can produce the same erection with fewer side effects from any single ingredient. The logic is straightforward: you get the benefit of all three mechanisms without needing a high dose of any one drug.

A head-to-head randomized trial compared trimix against alprostadil alone and found no significant differences in blood flow measurements, rigidity, patient satisfaction, or pain. Trimix did produce longer-lasting erections, though that came with a higher rate of priapism (erections that won’t go down).⁶ That study also showed that even the lowest doses of trimix ingredients matched alprostadil’s performance, which gives doctors room to fine-tune the mixture for each patient.

Where trimix really shines is in harder-to-treat cases. In a study comparing responses to alprostadil versus trimix in men with ED, 60% of the ED patients achieved a satisfactory response to a standard trimix dose, compared to only about 47% who responded to the equivalent alprostadil dose after two attempts.⁷ For men with more severe vascular damage, that gap in response rates can make trimix the difference between a treatment that works and one that doesn’t.

A practical advantage of trimix is cost. Because papaverine and phentolamine are inexpensive generic drugs, compounded trimix often costs less per injection than branded alprostadil (sold as Caverject or Edex). The trade-off is that trimix isn’t FDA-approved as a combination product. It has to be mixed by a compounding pharmacy, which introduces variability in quality and shelf life.

Bimix and Quadmix

Bimix is a two-drug combination, and the ingredients vary. The most common version pairs papaverine with phentolamine, leaving out the more expensive alprostadil. A newer formulation using papaverine plus chlorpromazine was tested in 167 men, with about 67% achieving strong erections at home. The complication rate was low at around 4%.⁸ Bimix is generally considered a step below trimix in terms of effectiveness, but it serves a role for men who can’t tolerate alprostadil or where cost is a barrier.

In a stepped treatment program for men with cardiovascular disease, about 54% responded to bimix, and among those who didn’t, roughly 75% responded when escalated to trimix. For the remaining non-responders, quadmix (trimix plus atropine) rescued about 57%.⁹ This stepped approach illustrates a common clinical pattern: start simpler and escalate only if needed.

Quadmix adds atropine to the trimix recipe. The theory is that atropine promotes the release of a natural vasodilator in penile tissue, boosting the effects of the other three drugs. After proper dose adjustment, studies suggest that 95-100% of patients can achieve a rigid erection with quadmix. But experts have noted that atropine is a relatively weak contributor, and quadmix is unlikely to rescue a patient who has genuinely failed high-dose trimix.¹⁰ The side effect profile is similar to trimix.

Priapism and How to Reduce the Risk

Priapism, an erection lasting more than four hours, is the most feared complication of injection therapy. It’s a medical emergency that can permanently damage the penis if untreated. In a large cross-sectional analysis of over 26,000 in-office injections, 4% of patients developed priapism. The vast majority of episodes happened within three days of the injection.¹¹

Younger men, those with lower body mass, and men with sickle cell disease were at higher risk. Men with diabetes, hypertension, or a history of prostate cancer were actually at lower risk, likely because those conditions cause enough vascular damage that the injection’s effects don’t overshoot as easily.¹¹ Among patients who experienced one episode of priapism, about a third had a second episode within a year, making careful dose titration essential after any event.

This is also where recreational misuse becomes dangerous. At one metropolitan center, recreational injections accounted for nearly half of all priapism cases presenting to the emergency department. Those patients tended to be younger and waited much longer before seeking help, with a median delay of 12 hours compared to 8 hours for other causes.¹² Waiting that long dramatically increases the risk of permanent damage. The lesson is blunt: these drugs should only be used under medical supervision with a properly titrated dose.

Fibrosis and Long-Term Penile Changes

Penile fibrosis, the formation of scar tissue or nodules in the shaft, is a well-known risk of long-term injection therapy. It was first documented extensively with papaverine, but alprostadil is not immune. One study found penile fibrosis in about 23% of men using alprostadil injections.¹³ The risk appears linked to how long you’ve been injecting and how frequently you do it.¹⁴

The four-year European alprostadil trial reported fibrotic changes in about 12% of men, with nearly half of those cases resolving spontaneously.² Good injection technique helps: rotating the injection site, using the correct needle gauge, and applying pressure after withdrawal all reduce the risk of developing scar tissue. Doctors typically recommend injecting no more than three times per week with at least 24 hours between sessions.

Why So Many Men Stop

Even when injection therapy works, a significant number of men abandon it. In a study of 720 men followed for an average of 38 months, the dropout rate was 31%. The surprising finding was that the main reasons were not about the drug failing. Instead, men left because of the cost, discomfort with the concept of injecting their penis, lack of a sexual partner, or because their erections spontaneously improved. Actual drug side effects were a minor contributor, and lack of efficacy was the primary reason for only about 1 in 7 dropouts.¹⁵

An earlier study found an even higher cumulative dropout rate of 46%, with the riskiest period being right after evaluation or during the initial dose-finding visits. Many men decided they simply couldn’t accept the idea of self-injection before ever giving it a sustained try.¹⁶ This psychological barrier is arguably the biggest obstacle the therapy faces. Doctors who take time to walk patients through the process and set realistic expectations tend to retain more patients. Customizing the dose so that pain and other side effects stay minimal also helps keep people on track.¹⁷

Long-Term Satisfaction

Satisfaction data paint a more nuanced picture than short-term efficacy numbers. In a study tracking men who used injections after prostate surgery, only 44% reported being satisfied or very satisfied at eight years, while 56% were unsatisfied or very unsatisfied.¹⁸ That’s a sharp contrast to the 87-94% satisfaction seen in shorter trials, and it reflects the cumulative burden of self-injection: the hassle, the loss of spontaneity, the discomfort, and the feeling that sex has become medicalized.

Still, for men whose erectile function scores start very low, the improvements can be dramatic. One long-term study showed IIEF erectile function scores nearly tripling with injection therapy, from around 12 to 27 on a 30-point scale.¹⁷ For some men, injection therapy is the only thing that has worked, and that context changes what “satisfied” means.

The Intraurethral Alternative

If the idea of a needle in the penis is a non-starter, intraurethral alprostadil (MUSE) delivers the same active drug through a tiny pellet inserted into the urethra. It avoids the injection entirely, along with the risks of fibrosis and priapism seen with intracavernosal use.¹⁹ Patients generally find it easier to accept, and preference studies show that men who try both methods tend to prefer the non-injection route.

The downside is reduced potency. Because the drug has to cross the urethral lining to reach the erectile tissue, much of it doesn’t make it there. Higher doses are needed, and the response rates are lower than with direct injection. MUSE works best for men with milder ED or as a bridge therapy for those who find injections psychologically difficult but need something stronger than oral medication.

Combining Injections with Oral Medication

One approach gaining traction is pairing injection therapy with a daily oral PDE5 inhibitor like tadalafil. The idea is that the oral drug keeps the smooth muscle tissue healthier and more responsive, potentially allowing a lower injection dose. Preliminary data from men who had radical prostatectomy suggest that those taking a daily PDE5 inhibitor were less likely to need increases in their trimix dose over time compared to men using trimix alone.²⁰ Lower doses mean less pain and less risk of priapism.

Lab work supports this combination. When trimix was paired with sildenafil, the resulting improvements in blood flow and the chemical signals that drive smooth muscle relaxation exceeded what either approach achieved alone.²¹ This isn’t something to try on your own, though. Combining vasodilators increases the risk of a dangerous drop in blood pressure or priapism, so it should only be done under a doctor’s supervision with careful dose adjustment.

VIP/Phentolamine as a Pain-Free Option

An alternative combination that replaces alprostadil with vasoactive intestinal polypeptide (VIP) paired with phentolamine has shown comparable effectiveness with dramatically less pain. In a two-phase comparison trial, alprostadil caused pain in 28% of injections, while the VIP/phentolamine combination caused pain in only about 3%. Interestingly, roughly 69% of patients preferred VIP/phentolamine over alprostadil, despite alprostadil’s slightly higher success rate in producing rigid erections (83% vs. 73% in the first phase). By the second phase, when doses were optimized, erection quality was equivalent across all formulations, and patient preference for VIP/phentolamine held firm.²² The main side effect was facial flushing, which occurred in about 16-17% of VIP/phentolamine injections versus 3% with alprostadil. For men who find alprostadil too painful, this is a meaningful alternative, though availability varies.

Storing Trimix Without Ruining It

Because trimix is compounded rather than commercially manufactured, storage matters more than with off-the-shelf alprostadil. Alprostadil is the weakest link in the mixture. At room temperature, about 8% of the alprostadil breaks down within five days. Refrigerated, you lose about 6% in one month and 11% in two months. Frozen at standard freezer temperature, all three ingredients remain stable for at least six months with less than 5% loss.²³

The practical takeaway: keep the vial frozen and thaw individual doses in the refrigerator as needed. Once thawed, the vial should stay refrigerated and used within a month. Leaving trimix on a nightstand or in a warm bathroom degrades the active ingredients quickly. If you travel, a small insulated bag with an ice pack is worth the trouble. A batch of trimix that’s lost a chunk of its alprostadil will feel weaker, pushing you toward a higher dose and increasing the risk of complications from the papaverine and phentolamine that are still fully potent.

Injections After Prostate Surgery

Men who’ve had a radical prostatectomy represent a particularly important group for injection therapy. The nerve bundles that control erection are often damaged during surgery, and even with nerve-sparing techniques, recovery of spontaneous erections can take a year or two. A meta-analysis confirmed that penile rehabilitation using PDE5 inhibitors, vacuum devices, or intracavernosal injections after prostatectomy significantly improves erectile function during treatment.²⁴

Injections serve a dual purpose in this population. They restore sexual function in the short term while the nerves heal, and they keep the penile tissue oxygenated and elastic during recovery, potentially preventing the structural deterioration that makes ED harder to treat later. The earlier finding about alprostadil promoting spontaneous erections over time is especially relevant here: some men who begin injecting after surgery eventually regain enough natural function to stop injecting altogether.

Men on Blood Thinners

A common concern is whether anticoagulant medications make penile injections too risky. In a retrospective study comparing men on blood thinners to those not taking them, bleeding complications occurred in about 7% of the anticoagulant group versus 0% in the control group. Despite the numerical difference, the study found no statistically significant increase in bleeding events, and the complications that did occur were minor.²⁵ Applying firm pressure to the injection site for several minutes and using a fine-gauge needle can further reduce bruising. Blood thinner use is not a reason to avoid injection therapy, but it is a reason to be more deliberate about technique.

1
PubMed. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction
2
International Journal of Impotence Research. Intracavernous Alprostadil Alfadex—an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study
3
PubMed. Return of spontaneous erection during long-term intracavernosal alprostadil (Caverject) treatment
4
PubMed. Incidence of penile pain after injection of a new formulation of prostaglandin E1
5
PubMed. Sexual rehabilitation and penile pain associated with intracavernous alprostadil after radical prostatectomy
6
International Journal of Impotence Research. A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1
7
PubMed Central. Evaluation of the sensitivity of different doses of vasoactive drugs in diagnosing erectile dysfunction in impotent patients: a prospective case-control study
8
PubMed. Intracavernous Self-injection of Papaverine Plus Chlorpromazine (Bimix) for the Treatment of Erectile Dysfunction
9
The American Journal of Cardiology. Treatment program for erectile dysfunction in patients with cardiovascular patients
10
Sexual Medicine Reviews. Evolving medical management of erectile dysfunction: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024)
11
International Journal of Impotence Research. Evaluating the management trends for priapism and assessing the risk of priapism after in-office intracavernosal injections: a cross-sectional analysis
12
PubMed Central. Priapism from Recreational Intracavernosal Injections in a High-Risk Metropolitan Community
13
International Journal of Impotence Research. Penile fibrosis in intracavernosal prostaglandin E1 injection therapy for erectile dysfunction
14
The Journal of Urology. Penile Scarring with Intracavernous Injection Therapy Using Prostaglandin E1: A Risk Factor Analysis
15
PubMed. The causes of patient dropout from penile self-injection therapy for impotence
16
PubMed. Why do so many people drop out from auto-injection therapy for impotence?
17
International Journal of Impotence Research. Long-term intracavernosal injection therapy: treatment efficacy and patient satisfaction
18
PubMed Central. Long-term satisfaction and predictors of use in patients using intracorporeal injections (ICI) for post-prostatectomy erectile dysfunction (PPED)
19
PubMed. Intraurethral alprostadil for erectile dysfunction: a review of the literature
20
The Journal of Sexual Medicine. EFFECT OF DAILY PHOSPHODIESTERASE 5 INHIBITOR USE ON TRIMIX INTRACORPOREAL INJECTION DOSAGE IN MEN WITH SEXUAL DYSFUNCTION FOLLOWING RADICAL PROSTATECTOMY
21
PubMed. Why a combined intracavernosal injection with trimix and oral sildenafil is reliable therapy in the ultrasonographic evaluation of erectile dysfunction
22
PubMed. Injection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilate
23
PubMed. Long-term stability of trimix: a three-drug injection used to treat erectile dysfunction
24
The Journal of Sexual Medicine. Penile Rehabilitation Therapy Following Radical Prostatectomy: A Meta-Analysis
25
PubMed Central. Complication Rates in Patients Using Intracavernosal Injection Therapy for Erectile Dysfunction With or Without Concurrent Anticoagulant Use—A Single-Center, Retrospective Pilot Study